Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa

Bibliography

• WHO World Malaria Report 2011. WHO. Available from: http://www.who.int/malaria/world_malaria_report_2011/9789241564403_eng.pdf
   Google Scholar
• Guidelines for the Treatment of Malaria: second Edition (2010). WHO. Available from: http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html
   Google Scholar
• White NJ, van VM, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999;37(2):105-25
   PubMed Web of Science ®Google Scholar
• Lefevre G, Thomsen MS. Clinical pharmacokinetics of artemether and lumefantrine (Riamet). Clin Drug Invest 1999;18:467-80
   Web of Science ®Google Scholar
• Test. Treat. Track. Scaling up diagnostic testing, treatment and surveillance for malaria. WHO
   Google Scholar
• Global plan for artemisinin resistance containment (GPARC). WHO. Available from: http://www.who.int/malaria/publications/atoz/artemisinin_resistance_containment_2011.pdf
   Google Scholar
• Novartis Drug Regulatory Affairs. Coartem/Riamet Dispersible Basic Prescribing Information; 2009
   Google Scholar
• Abdulla S, Sagara I, Borrmann S, Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008;372(9652):1819-27
   PubMedGoogle Scholar
• Manyando C, Mkandawire R, Puma L, Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J 2010;9:249
   PubMed Web of Science ®Google Scholar
• Virtanen M, Marrast AC. Artemether-Lumefantrine (Co-artemether) Investigator's Brochure; 2009
   Google Scholar
• Sinclair D, Zani B, Donegan S, Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009(3):CD007483
   PubMed Web of Science ®Google Scholar
• Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother 2007;8(1):75-94
   PubMed Web of Science ®Google Scholar
• Ezzet F, van Vugt M, Nosten F, Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000;44(3):697-704
   PubMed Web of Science ®Google Scholar
• White NJ. Antimalarial pharmacokinetics and treatment regimens. Br J Clin Pharmacol 1992;34(1):1-10
   PubMedGoogle Scholar
• Kabanywanyi AM, Lengeler C, Kasim P, Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Malar J 2010;9:48
   PubMed Web of Science ®Google Scholar
• Novartis Drug Regulatory Affairs. Coartem/Riamet Basic Prescribing Information; 2009
   Google Scholar
• Fitch CD. Involvement of heme in the antimalarial action of chloroquine. Trans Am Clin Climatol Assoc 1998;109:97-105
   PubMedGoogle Scholar
• Lefevre G, Bindschedler M, Ezzet F, Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur J Pharm Sci 2000;10(2):141-51
   PubMedGoogle Scholar
• Premji ZG, Abdulla S, Ogutu B, The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Malar J 2008;7:244
   PubMedGoogle Scholar
• Borrmann S, Sallas WM, Machevo S, The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2010;15(4):434-41
   PubMed Web of Science ®Google Scholar
• Djimde A, Lefevre G. Understanding the pharmacokinetics of Coartem. Malar J 2009;8(Suppl 1):S4
   PubMed Web of Science ®Google Scholar
• White NJ. Antimalarial drug resistance. J Clin Invest 2004;113(8):1084-92
   PubMed Web of Science ®Google Scholar
• Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 2008;52(5):1589-96
   PubMed Web of Science ®Google Scholar
• Pillai DR, Lau R, Khairnar K, Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections. Malar J 2012;11:131
   PubMed Web of Science ®Google Scholar
• Wang Z, Parker D, Meng H, In vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genes. PLoS ONE 2012;7(5):e30927
   Google Scholar
• Mwai L, Diriye A, Masseno V, Genome wide adaptations of Plasmodium falciparum in response to lumefantrine selective drug pressure. PLoS ONE 2012;7(2):e31623
   PubMed Web of Science ®Google Scholar
• Cheeseman I, Miller B, Nair S, A major genome region underlying artemisinin resistance in malaria. Science 2012;336(6077):79-82
   PubMed Web of Science ®Google Scholar
• Makanga M, Bassat Q, Falade CO, Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg 2011;85(5):793-804
   PubMedGoogle Scholar
• Adjei GO, Kurtzhals JA, Rodrigues OP, Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J 2008;7:127
   PubMed Web of Science ®Google Scholar
• Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J 2008;7:106
   PubMedGoogle Scholar
• Okell LC, Drakeley CJ, Ghani AC, Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J 2008;7:125
   PubMed Web of Science ®Google Scholar
• Beshir KB, Sawa P, Drakeley CJ, Extended malaria parasite clearance time in African children following artemisinin-combination therapy enhances transmission to Anopheles mosquitoes. Available from: http://www.malariajournal.com/content/11/S1/O20
   Google Scholar
• Barrington J, Wereko-Brobby O, Ward P, SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology. Malar J 2010;9:298
   PubMed Web of Science ®Google Scholar
• Piola P, Nabasumba C, Turyakira E, Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis 2010;10(11):762-9
   PubMed Web of Science ®Google Scholar
• McGready R, Phyo AP, Rijken MJ, Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol 2012;73(3):467-77
   PubMed Web of Science ®Google Scholar
• Falade C, Makanga M, Premji Z, Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2005;99(6):459-67
   PubMedGoogle Scholar